-
England is set to approve cabotegravir, a two-month injectable HIV prevention shot, expanding options for those unable to take daily pills. Zimbabwe will roll out lenacapavir, a twice-yearly prophylactic, amid debates over cost and safety. Both developments mark significant advances in HIV prevention efforts.
-
As of December 2025, the WHO has issued its first guidelines recommending long-term use of GLP-1 medications like Wegovy and Mounjaro for obesity treatment, recognizing obesity as a chronic disease. The US government has negotiated significant price cuts for these drugs, expanding Medicare and Medicaid coverage to more patients. However, concerns remain about drug accessibility, side effects, and weight regain after stopping treatment.
-
The UK and US have agreed to a trade deal that maintains 0% import taxes on medicines for three years, while increasing the NHS's drug spending threshold by 25%. The deal aims to boost investment, protect jobs, and facilitate access to innovative medicines, amid ongoing industry concerns over investment and pricing practices.
-
A UK-led trial is testing whether Aquablation, a robotic waterjet therapy, can treat localized prostate cancer as effectively as traditional surgery, with fewer side effects. The trial involves seven countries and aims to improve quality of life for patients.